Global Graves Disease Market

Graves Disease Comprehensive Study by Type (Anti-Thyroid Drugs, Lodine and Iodides, Radioactive Lodine, Lonic Inhibitors), Application (Hospital, Specialty Clinics), Distribution Channel (Hospital Dispensary, Retail Pharmacy, Online Pharmacy), Medication (Propylthiouracil, Methimazole, Others) Players and Region - Global Market Outlook to 2030

Graves Disease Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Graves Disease Market Scope
In the developing world, Graves' disease is the most frequent cause of hyperthyroidism. It is caused by an immune deficiency in genetically prone people, resulting in thyroid hormone overload and glandular hyperplasia due to the development of special antibodies. Graves' disease reduces quality of life and increases the risk of psychosis, tachyarrhythmia, and heart failure. Graves' disease has a variety of soft-tissue symptoms that indicate its systemic autoimmune nature. Thyroid eye disorder is the most frequent of these manifestations, and it is critical to recognise it because of the risk to vision and the possibility for worsening in response to radioactive iodine ablation. Graves is a treatable and well-managed condition. Any patients will experience recovery, but many need long-term therapy for this illness.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), GlaxoSmithKline plc (United Kingdom), Merck and Co (United States), Pfizer, Inc (United States), RLC LABS (United States), AbbVie, Inc (United States), Mylan N.V. (United States), Allergan, plc (United States), advanceCor GmbH. (Germany) and Apitope International NV. (Belgium)
CAGR%


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Graves Disease market throughout the predicted period.

Abbott Laboratories (United States), GlaxoSmithKline plc (United Kingdom), Merck and Co (United States), Pfizer, Inc (United States), RLC LABS (United States), AbbVie, Inc (United States), Mylan N.V. (United States), Allergan, plc (United States), advanceCor GmbH. (Germany) and Apitope International NV. (Belgium) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are AV7 Ltd. (United Kingdom), Omeros Corp. (United States) and HanAll Biopharma. (South Korea).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Graves Disease market by Type , by Application (Hospital and Specialty Clinics) and Region with country level break-up.

On the basis of geography, the market of Graves Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In Jaunuary, 2020, American Association of Clinical Endocrinologists (AACE) Released ‘Up to Here’ Thyroid Awareness Campaign. The Campaign its Aimed to Help Patients Recognize Symptoms, Risk Factors and The Need to Seek Treatment.
In June, 2019 - Eyes on Graves' Initiative Announced the launch of oneGRAVESvoice.com, for Awareness Among the People Living with Graves' Disease and Thyroid Eye Disease. The GDATF Manages Onegravesvoice, An Immersive Online Destination.


Influencing Trend:
Emergence of Advance Surgical Procedures

Market Growth Drivers:
Prevalence of Graves Disease, Rising Geriatric Population and Technical Progress in Healthcare Industries

Challenges:
Skewed Player Distribution

Restraints:
Lack of Trained Professionals

Opportunities:
Increasing Penetration across Emerging Regions and Growing Healthcare Infrastructure

Key Target Audience
Graves Disease Medication Manufactures, New Entrants and Investors, Graves Disease Medication Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Anti-Thyroid Drugs
  • Lodine and Iodides
  • Radioactive Lodine
  • Lonic Inhibitors
By Application
  • Hospital
  • Specialty Clinics
By Distribution Channel
  • Hospital Dispensary
  • Retail Pharmacy
  • Online Pharmacy

By Medication
  • Propylthiouracil
  • Methimazole
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Graves Disease
      • 3.2.2. Rising Geriatric Population
      • 3.2.3. Technical Progress in Healthcare Industries
    • 3.3. Market Challenges
      • 3.3.1. Skewed Player Distribution
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advance Surgical Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Graves Disease, by Type, Application, Distribution Channel, Medication and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Graves Disease (Value)
      • 5.2.1. Global Graves Disease by: Type (Value)
        • 5.2.1.1. Anti-Thyroid Drugs
        • 5.2.1.2. Lodine and Iodides
        • 5.2.1.3. Radioactive Lodine
        • 5.2.1.4. Lonic Inhibitors
      • 5.2.2. Global Graves Disease by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Specialty Clinics
      • 5.2.3. Global Graves Disease by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Dispensary
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Pharmacy
      • 5.2.4. Global Graves Disease by: Medication (Value)
        • 5.2.4.1. Propylthiouracil
        • 5.2.4.2. Methimazole
        • 5.2.4.3. Others
      • 5.2.5. Global Graves Disease Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Graves Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck and Co (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. RLC LABS (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AbbVie, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N.V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan, plc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AdvanceCor GmbH. (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Apitope International NV. (Belgium)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Graves Disease Sale, by Type, Application, Distribution Channel, Medication and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Graves Disease (Value)
      • 7.2.1. Global Graves Disease by: Type (Value)
        • 7.2.1.1. Anti-Thyroid Drugs
        • 7.2.1.2. Lodine and Iodides
        • 7.2.1.3. Radioactive Lodine
        • 7.2.1.4. Lonic Inhibitors
      • 7.2.2. Global Graves Disease by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Specialty Clinics
      • 7.2.3. Global Graves Disease by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Dispensary
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Pharmacy
      • 7.2.4. Global Graves Disease by: Medication (Value)
        • 7.2.4.1. Propylthiouracil
        • 7.2.4.2. Methimazole
        • 7.2.4.3. Others
      • 7.2.5. Global Graves Disease Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Graves Disease: by Type(USD Million)
  • Table 2. Graves Disease Anti-Thyroid Drugs , by Region USD Million (2018-2023)
  • Table 3. Graves Disease Lodine and Iodides , by Region USD Million (2018-2023)
  • Table 4. Graves Disease Radioactive Lodine , by Region USD Million (2018-2023)
  • Table 5. Graves Disease Lonic Inhibitors , by Region USD Million (2018-2023)
  • Table 6. Graves Disease: by Application(USD Million)
  • Table 7. Graves Disease Hospital , by Region USD Million (2018-2023)
  • Table 8. Graves Disease Specialty Clinics , by Region USD Million (2018-2023)
  • Table 9. Graves Disease: by Distribution Channel(USD Million)
  • Table 10. Graves Disease Hospital Dispensary , by Region USD Million (2018-2023)
  • Table 11. Graves Disease Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Graves Disease Online Pharmacy , by Region USD Million (2018-2023)
  • Table 13. Graves Disease: by Medication(USD Million)
  • Table 14. Graves Disease Propylthiouracil , by Region USD Million (2018-2023)
  • Table 15. Graves Disease Methimazole , by Region USD Million (2018-2023)
  • Table 16. Graves Disease Others , by Region USD Million (2018-2023)
  • Table 17. South America Graves Disease, by Country USD Million (2018-2023)
  • Table 18. South America Graves Disease, by Type USD Million (2018-2023)
  • Table 19. South America Graves Disease, by Application USD Million (2018-2023)
  • Table 20. South America Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 21. South America Graves Disease, by Medication USD Million (2018-2023)
  • Table 22. Brazil Graves Disease, by Type USD Million (2018-2023)
  • Table 23. Brazil Graves Disease, by Application USD Million (2018-2023)
  • Table 24. Brazil Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 25. Brazil Graves Disease, by Medication USD Million (2018-2023)
  • Table 26. Argentina Graves Disease, by Type USD Million (2018-2023)
  • Table 27. Argentina Graves Disease, by Application USD Million (2018-2023)
  • Table 28. Argentina Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 29. Argentina Graves Disease, by Medication USD Million (2018-2023)
  • Table 30. Rest of South America Graves Disease, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Graves Disease, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 33. Rest of South America Graves Disease, by Medication USD Million (2018-2023)
  • Table 34. Asia Pacific Graves Disease, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Graves Disease, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Graves Disease, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 38. Asia Pacific Graves Disease, by Medication USD Million (2018-2023)
  • Table 39. China Graves Disease, by Type USD Million (2018-2023)
  • Table 40. China Graves Disease, by Application USD Million (2018-2023)
  • Table 41. China Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 42. China Graves Disease, by Medication USD Million (2018-2023)
  • Table 43. Japan Graves Disease, by Type USD Million (2018-2023)
  • Table 44. Japan Graves Disease, by Application USD Million (2018-2023)
  • Table 45. Japan Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 46. Japan Graves Disease, by Medication USD Million (2018-2023)
  • Table 47. India Graves Disease, by Type USD Million (2018-2023)
  • Table 48. India Graves Disease, by Application USD Million (2018-2023)
  • Table 49. India Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 50. India Graves Disease, by Medication USD Million (2018-2023)
  • Table 51. South Korea Graves Disease, by Type USD Million (2018-2023)
  • Table 52. South Korea Graves Disease, by Application USD Million (2018-2023)
  • Table 53. South Korea Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 54. South Korea Graves Disease, by Medication USD Million (2018-2023)
  • Table 55. Taiwan Graves Disease, by Type USD Million (2018-2023)
  • Table 56. Taiwan Graves Disease, by Application USD Million (2018-2023)
  • Table 57. Taiwan Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 58. Taiwan Graves Disease, by Medication USD Million (2018-2023)
  • Table 59. Australia Graves Disease, by Type USD Million (2018-2023)
  • Table 60. Australia Graves Disease, by Application USD Million (2018-2023)
  • Table 61. Australia Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 62. Australia Graves Disease, by Medication USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Graves Disease, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Graves Disease, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Graves Disease, by Medication USD Million (2018-2023)
  • Table 67. Europe Graves Disease, by Country USD Million (2018-2023)
  • Table 68. Europe Graves Disease, by Type USD Million (2018-2023)
  • Table 69. Europe Graves Disease, by Application USD Million (2018-2023)
  • Table 70. Europe Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 71. Europe Graves Disease, by Medication USD Million (2018-2023)
  • Table 72. Germany Graves Disease, by Type USD Million (2018-2023)
  • Table 73. Germany Graves Disease, by Application USD Million (2018-2023)
  • Table 74. Germany Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 75. Germany Graves Disease, by Medication USD Million (2018-2023)
  • Table 76. France Graves Disease, by Type USD Million (2018-2023)
  • Table 77. France Graves Disease, by Application USD Million (2018-2023)
  • Table 78. France Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 79. France Graves Disease, by Medication USD Million (2018-2023)
  • Table 80. Italy Graves Disease, by Type USD Million (2018-2023)
  • Table 81. Italy Graves Disease, by Application USD Million (2018-2023)
  • Table 82. Italy Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 83. Italy Graves Disease, by Medication USD Million (2018-2023)
  • Table 84. United Kingdom Graves Disease, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Graves Disease, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 87. United Kingdom Graves Disease, by Medication USD Million (2018-2023)
  • Table 88. Netherlands Graves Disease, by Type USD Million (2018-2023)
  • Table 89. Netherlands Graves Disease, by Application USD Million (2018-2023)
  • Table 90. Netherlands Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 91. Netherlands Graves Disease, by Medication USD Million (2018-2023)
  • Table 92. Rest of Europe Graves Disease, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Graves Disease, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 95. Rest of Europe Graves Disease, by Medication USD Million (2018-2023)
  • Table 96. MEA Graves Disease, by Country USD Million (2018-2023)
  • Table 97. MEA Graves Disease, by Type USD Million (2018-2023)
  • Table 98. MEA Graves Disease, by Application USD Million (2018-2023)
  • Table 99. MEA Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 100. MEA Graves Disease, by Medication USD Million (2018-2023)
  • Table 101. Middle East Graves Disease, by Type USD Million (2018-2023)
  • Table 102. Middle East Graves Disease, by Application USD Million (2018-2023)
  • Table 103. Middle East Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 104. Middle East Graves Disease, by Medication USD Million (2018-2023)
  • Table 105. Africa Graves Disease, by Type USD Million (2018-2023)
  • Table 106. Africa Graves Disease, by Application USD Million (2018-2023)
  • Table 107. Africa Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 108. Africa Graves Disease, by Medication USD Million (2018-2023)
  • Table 109. North America Graves Disease, by Country USD Million (2018-2023)
  • Table 110. North America Graves Disease, by Type USD Million (2018-2023)
  • Table 111. North America Graves Disease, by Application USD Million (2018-2023)
  • Table 112. North America Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 113. North America Graves Disease, by Medication USD Million (2018-2023)
  • Table 114. United States Graves Disease, by Type USD Million (2018-2023)
  • Table 115. United States Graves Disease, by Application USD Million (2018-2023)
  • Table 116. United States Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 117. United States Graves Disease, by Medication USD Million (2018-2023)
  • Table 118. Canada Graves Disease, by Type USD Million (2018-2023)
  • Table 119. Canada Graves Disease, by Application USD Million (2018-2023)
  • Table 120. Canada Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 121. Canada Graves Disease, by Medication USD Million (2018-2023)
  • Table 122. Mexico Graves Disease, by Type USD Million (2018-2023)
  • Table 123. Mexico Graves Disease, by Application USD Million (2018-2023)
  • Table 124. Mexico Graves Disease, by Distribution Channel USD Million (2018-2023)
  • Table 125. Mexico Graves Disease, by Medication USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Graves Disease: by Type(USD Million)
  • Table 137. Graves Disease Anti-Thyroid Drugs , by Region USD Million (2025-2030)
  • Table 138. Graves Disease Lodine and Iodides , by Region USD Million (2025-2030)
  • Table 139. Graves Disease Radioactive Lodine , by Region USD Million (2025-2030)
  • Table 140. Graves Disease Lonic Inhibitors , by Region USD Million (2025-2030)
  • Table 141. Graves Disease: by Application(USD Million)
  • Table 142. Graves Disease Hospital , by Region USD Million (2025-2030)
  • Table 143. Graves Disease Specialty Clinics , by Region USD Million (2025-2030)
  • Table 144. Graves Disease: by Distribution Channel(USD Million)
  • Table 145. Graves Disease Hospital Dispensary , by Region USD Million (2025-2030)
  • Table 146. Graves Disease Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 147. Graves Disease Online Pharmacy , by Region USD Million (2025-2030)
  • Table 148. Graves Disease: by Medication(USD Million)
  • Table 149. Graves Disease Propylthiouracil , by Region USD Million (2025-2030)
  • Table 150. Graves Disease Methimazole , by Region USD Million (2025-2030)
  • Table 151. Graves Disease Others , by Region USD Million (2025-2030)
  • Table 152. South America Graves Disease, by Country USD Million (2025-2030)
  • Table 153. South America Graves Disease, by Type USD Million (2025-2030)
  • Table 154. South America Graves Disease, by Application USD Million (2025-2030)
  • Table 155. South America Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 156. South America Graves Disease, by Medication USD Million (2025-2030)
  • Table 157. Brazil Graves Disease, by Type USD Million (2025-2030)
  • Table 158. Brazil Graves Disease, by Application USD Million (2025-2030)
  • Table 159. Brazil Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 160. Brazil Graves Disease, by Medication USD Million (2025-2030)
  • Table 161. Argentina Graves Disease, by Type USD Million (2025-2030)
  • Table 162. Argentina Graves Disease, by Application USD Million (2025-2030)
  • Table 163. Argentina Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 164. Argentina Graves Disease, by Medication USD Million (2025-2030)
  • Table 165. Rest of South America Graves Disease, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Graves Disease, by Application USD Million (2025-2030)
  • Table 167. Rest of South America Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 168. Rest of South America Graves Disease, by Medication USD Million (2025-2030)
  • Table 169. Asia Pacific Graves Disease, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Graves Disease, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Graves Disease, by Application USD Million (2025-2030)
  • Table 172. Asia Pacific Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 173. Asia Pacific Graves Disease, by Medication USD Million (2025-2030)
  • Table 174. China Graves Disease, by Type USD Million (2025-2030)
  • Table 175. China Graves Disease, by Application USD Million (2025-2030)
  • Table 176. China Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 177. China Graves Disease, by Medication USD Million (2025-2030)
  • Table 178. Japan Graves Disease, by Type USD Million (2025-2030)
  • Table 179. Japan Graves Disease, by Application USD Million (2025-2030)
  • Table 180. Japan Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 181. Japan Graves Disease, by Medication USD Million (2025-2030)
  • Table 182. India Graves Disease, by Type USD Million (2025-2030)
  • Table 183. India Graves Disease, by Application USD Million (2025-2030)
  • Table 184. India Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 185. India Graves Disease, by Medication USD Million (2025-2030)
  • Table 186. South Korea Graves Disease, by Type USD Million (2025-2030)
  • Table 187. South Korea Graves Disease, by Application USD Million (2025-2030)
  • Table 188. South Korea Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 189. South Korea Graves Disease, by Medication USD Million (2025-2030)
  • Table 190. Taiwan Graves Disease, by Type USD Million (2025-2030)
  • Table 191. Taiwan Graves Disease, by Application USD Million (2025-2030)
  • Table 192. Taiwan Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 193. Taiwan Graves Disease, by Medication USD Million (2025-2030)
  • Table 194. Australia Graves Disease, by Type USD Million (2025-2030)
  • Table 195. Australia Graves Disease, by Application USD Million (2025-2030)
  • Table 196. Australia Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 197. Australia Graves Disease, by Medication USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Graves Disease, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Graves Disease, by Application USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Graves Disease, by Medication USD Million (2025-2030)
  • Table 202. Europe Graves Disease, by Country USD Million (2025-2030)
  • Table 203. Europe Graves Disease, by Type USD Million (2025-2030)
  • Table 204. Europe Graves Disease, by Application USD Million (2025-2030)
  • Table 205. Europe Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 206. Europe Graves Disease, by Medication USD Million (2025-2030)
  • Table 207. Germany Graves Disease, by Type USD Million (2025-2030)
  • Table 208. Germany Graves Disease, by Application USD Million (2025-2030)
  • Table 209. Germany Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 210. Germany Graves Disease, by Medication USD Million (2025-2030)
  • Table 211. France Graves Disease, by Type USD Million (2025-2030)
  • Table 212. France Graves Disease, by Application USD Million (2025-2030)
  • Table 213. France Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 214. France Graves Disease, by Medication USD Million (2025-2030)
  • Table 215. Italy Graves Disease, by Type USD Million (2025-2030)
  • Table 216. Italy Graves Disease, by Application USD Million (2025-2030)
  • Table 217. Italy Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 218. Italy Graves Disease, by Medication USD Million (2025-2030)
  • Table 219. United Kingdom Graves Disease, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Graves Disease, by Application USD Million (2025-2030)
  • Table 221. United Kingdom Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 222. United Kingdom Graves Disease, by Medication USD Million (2025-2030)
  • Table 223. Netherlands Graves Disease, by Type USD Million (2025-2030)
  • Table 224. Netherlands Graves Disease, by Application USD Million (2025-2030)
  • Table 225. Netherlands Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 226. Netherlands Graves Disease, by Medication USD Million (2025-2030)
  • Table 227. Rest of Europe Graves Disease, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Graves Disease, by Application USD Million (2025-2030)
  • Table 229. Rest of Europe Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 230. Rest of Europe Graves Disease, by Medication USD Million (2025-2030)
  • Table 231. MEA Graves Disease, by Country USD Million (2025-2030)
  • Table 232. MEA Graves Disease, by Type USD Million (2025-2030)
  • Table 233. MEA Graves Disease, by Application USD Million (2025-2030)
  • Table 234. MEA Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 235. MEA Graves Disease, by Medication USD Million (2025-2030)
  • Table 236. Middle East Graves Disease, by Type USD Million (2025-2030)
  • Table 237. Middle East Graves Disease, by Application USD Million (2025-2030)
  • Table 238. Middle East Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 239. Middle East Graves Disease, by Medication USD Million (2025-2030)
  • Table 240. Africa Graves Disease, by Type USD Million (2025-2030)
  • Table 241. Africa Graves Disease, by Application USD Million (2025-2030)
  • Table 242. Africa Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 243. Africa Graves Disease, by Medication USD Million (2025-2030)
  • Table 244. North America Graves Disease, by Country USD Million (2025-2030)
  • Table 245. North America Graves Disease, by Type USD Million (2025-2030)
  • Table 246. North America Graves Disease, by Application USD Million (2025-2030)
  • Table 247. North America Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 248. North America Graves Disease, by Medication USD Million (2025-2030)
  • Table 249. United States Graves Disease, by Type USD Million (2025-2030)
  • Table 250. United States Graves Disease, by Application USD Million (2025-2030)
  • Table 251. United States Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 252. United States Graves Disease, by Medication USD Million (2025-2030)
  • Table 253. Canada Graves Disease, by Type USD Million (2025-2030)
  • Table 254. Canada Graves Disease, by Application USD Million (2025-2030)
  • Table 255. Canada Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 256. Canada Graves Disease, by Medication USD Million (2025-2030)
  • Table 257. Mexico Graves Disease, by Type USD Million (2025-2030)
  • Table 258. Mexico Graves Disease, by Application USD Million (2025-2030)
  • Table 259. Mexico Graves Disease, by Distribution Channel USD Million (2025-2030)
  • Table 260. Mexico Graves Disease, by Medication USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Graves Disease: by Type USD Million (2018-2023)
  • Figure 5. Global Graves Disease: by Application USD Million (2018-2023)
  • Figure 6. Global Graves Disease: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Graves Disease: by Medication USD Million (2018-2023)
  • Figure 8. South America Graves Disease Share (%), by Country
  • Figure 9. Asia Pacific Graves Disease Share (%), by Country
  • Figure 10. Europe Graves Disease Share (%), by Country
  • Figure 11. MEA Graves Disease Share (%), by Country
  • Figure 12. North America Graves Disease Share (%), by Country
  • Figure 13. Global Graves Disease share by Players 2023 (%)
  • Figure 14. Global Graves Disease share by Players (Top 3) 2023(%)
  • Figure 15. Global Graves Disease share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Merck and Co (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck and Co (United States) Revenue: by Geography 2023
  • Figure 23. Pfizer, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer, Inc (United States) Revenue: by Geography 2023
  • Figure 25. RLC LABS (United States) Revenue, Net Income and Gross profit
  • Figure 26. RLC LABS (United States) Revenue: by Geography 2023
  • Figure 27. AbbVie, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie, Inc (United States) Revenue: by Geography 2023
  • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 31. Allergan, plc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Allergan, plc (United States) Revenue: by Geography 2023
  • Figure 33. AdvanceCor GmbH. (Germany) Revenue, Net Income and Gross profit
  • Figure 34. AdvanceCor GmbH. (Germany) Revenue: by Geography 2023
  • Figure 35. Apitope International NV. (Belgium) Revenue, Net Income and Gross profit
  • Figure 36. Apitope International NV. (Belgium) Revenue: by Geography 2023
  • Figure 37. Global Graves Disease: by Type USD Million (2025-2030)
  • Figure 38. Global Graves Disease: by Application USD Million (2025-2030)
  • Figure 39. Global Graves Disease: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Graves Disease: by Medication USD Million (2025-2030)
  • Figure 41. South America Graves Disease Share (%), by Country
  • Figure 42. Asia Pacific Graves Disease Share (%), by Country
  • Figure 43. Europe Graves Disease Share (%), by Country
  • Figure 44. MEA Graves Disease Share (%), by Country
  • Figure 45. North America Graves Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Merck and Co (United States)
  • Pfizer, Inc (United States)
  • RLC LABS (United States)
  • AbbVie, Inc (United States)
  • Mylan N.V. (United States)
  • Allergan, plc (United States)
  • advanceCor GmbH. (Germany)
  • Apitope International NV. (Belgium)
Additional players considered in the study are as follows:
AV7 Ltd. (United Kingdom) , Omeros Corp. (United States) , HanAll Biopharma. (South Korea)
Select User Access Type

Key Highlights of Report


Feb 2024 250 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Graves Disease Market Quantitative research analysis
Global Graves Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Graves Disease Market are by type [Anti-Thyroid Drugs, Lodine and Iodides, Radioactive Lodine and Lonic Inhibitors], by end use application [Hospital and Specialty Clinics].
The Graves Disease Market is gaining popularity and expected to see strong valuation by 2030.
  • Prevalence of Graves Disease
  • Rising Geriatric Population
  • Technical Progress in Healthcare Industries

Know More About Global Graves Disease Market Report?

Have a Query? Click Here

Other Related Reports

Dystrophic Epidermolysis Bullosa Treatment Comprehensive Study by Therapy (Gene therapy, Bone Marrow (Stem Cell) Transplantation, Protein Replacement Therapies, Cell-based Therapies), Treatment (Anti...
$ 3750
Cutaneous T-cell Lymphomas (CTCL) Comprehensive Study by Type (Mycosis Fungoides (MF), Sezary Syndrome (SS), Others), Treatment (Radiation Therapy, Chemotherapy, Immunotherapy, Targeted therapy, Othe...
$ 3500
Lichen Nitidus Treatment Comprehensive Study by Type (Corticosteroids, Retinoid, Antihistamines, Phototherapy), Route of Administration (Topical, Oral), Diagnosis (Electrocardiogram, Electrophysiolog...
$ 3450
Breast Cancer Diagnostics Comprehensive Study by Type (Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomo...
$ 3750
Dyspnea Treatment Comprehensive Study by Type (Therapy (Supplemental Oxygen Therapy, Relaxation Therapy), Drugs (Antianxiety Drugs, Antibiotics, Anticholinergic Agents, Corticosteroids, Others)), App...
$ 3650
Reflux Nephropathy Treatment Comprehensive Study by Type (Prophylactic Antibiotics, Antihypertensive Medications, Pain Medications, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmac...
$ 3350